ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamental Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) shows moderate financial fundamentals with a PE ratio of -5.04, profit margin of -1.37%, and ROE of -32.79%. The company generates $0.2B in annual revenue with strong year-over-year growth of 191.10%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -89.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1541.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1541.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1541.HK trades at attractive valuation levels.
Growth Score
Excellent1541.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent1541.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1541.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1541.HK Expensive or Cheap?
P/E Ratio
1541.HK trades at -5.04 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1541.HK's PEG of -0.14 indicates potential undervaluation.
Price to Book
The market values ImmuneOnco Biopharmaceuticals (Shanghai) Inc. at 1.38 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -7.51 times EBITDA. This is generally considered low.
How Well Does 1541.HK Make Money?
Net Profit Margin
For every $100 in sales, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. keeps $-1.37 as profit after all expenses.
Operating Margin
Core operations generate -1.36 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-32.79 in profit for every $100 of shareholder equity.
ROA
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. generates $-19.79 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. generates limited operating cash flow of $-201.49M, signaling weaker underlying cash strength.
Free Cash Flow
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. generates weak or negative free cash flow of $-202.78M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.48 in free cash annually.
FCF Yield
1541.HK converts -18.89% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-5.04
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.14
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.38
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.85
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.83
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.33
vs 25 benchmark
ROA
Return on assets percentage
-0.20
vs 25 benchmark
ROCE
Return on capital employed
-0.26
vs 25 benchmark
How 1541.HK Stacks Against Its Sector Peers
| Metric | 1541.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -5.04 | 28.32 | Better (Cheaper) |
| ROE | -32.79% | 733.00% | Weak |
| Net Margin | -137.35% | -53055.00% (disorted) | Weak |
| Debt/Equity | 0.29 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 3.83 | 4.03 | Strong Liquidity |
| ROA | -19.79% | -19488.00% (disorted) | Weak |
1541.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1348.18%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
57.35%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
33.50%
Industry Style: Defensive, Growth, Innovation
High Growth